Sus Clinicals

Sus Clinicals operates as a specialized preclinical contract research service provider, focusing on oncology. Its core asset is the FDA-cleared Oncopig® platform, a genetically-engineered porcine model that allows for the on-demand induction of tumors and comorbidities, offering a physiologically relevant alternative to traditional mouse models for testing therapeutics, diagnostics, and medical devices. The company employs a capital-light partnership model, collaborating with established CROs like CBSET, NAMSA, MED Institute, and Veranex to deliver studies, while also supplying animals and training directly to qualified clients. With a new CEO appointed in 2024 and strategic European expansion via Versa Biomedical, Sus Clinicals is positioning itself to capture a share of the growing demand for more predictive preclinical testing in oncology and beyond.

Genetically-engineered Oncopig® platform (FDA-cleared) enabling on-demand induction of site- and cell-type-specific tumors and comorbidities in pigs, providing a physiologically relevant preclinical model for testing drugs, diagnostics, and medical devices.

Sus Clinicals competes with traditional rodent-based CRO services and other large animal model providers (e.g., non-human primate, dog models). Its primary differentiation is the proprietary, genetically-defined Oncopig® model. Competition also comes from in-house research at large pharma and academic institutions, as well as other emerging humanized mouse or organ-on-a-chip technologies aiming to improve preclinical prediction.